Prof Jeanne Tie
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
343 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Diagnostic and predictive utility of peritoneal tumor DNA in gastroesophageal cancer: A prospective multicenter study.
DOI: 10.1200/jco.2026.44.16_suppl.41012026
Journal article
The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H.
DOI: 10.1200/JCO.2026.44.16_suppl.TPS36762026
Journal article
Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective
DOI: 10.1016/j.clcc.2026.04.0012026
Journal article
Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.16_suppl.tps36752026
Journal article
Implementing targeted thromboprophylaxis as a supportive care model: Mapping implementation preferences across the cancer care pathway.
DOI: 10.1200/jco.2026.44.16_suppl.e135522026
Journal article
Value of risk-directed thromboprophylaxis in ambulatory lung and gastrointestinal cancer care: Economic evaluation of the TARGET-TP randomized trial.
DOI: 10.1200/jco.2026.44.16_suppl.121372026
Research grants (ARC, NHMRC, MRFF)
Advancing Precision Medicine for Colorectal Cancer Through Liquid Biopsy
RECENT SCHOLARLY WORKS
2026
Journal article
Circulating tumour DNA in colorectal cancer: current and emerging clinical applications
DOI: 10.20935/acadonco82792026
Journal article
How Survivors of Colorectal Cancer Experience ctDNA Testing and Fear of Recurrence
DOI: 10.1002/pon.704642026
Journal article
Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial
DOI: 10.1001/jamaoncol.2025.61962026
Journal article
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial.
DOI: 10.1093/jnci/djag065